Molecular association of pathogenetic contributors to pre-eclampsia (pre-eclampsia associome)

BMC Systems Biology
|April 17, 2015
PubMed

Insights

This study reveals that comorbid diseases like pre-eclampsia, diabetes mellitus, gestational diabetes, and obesity share complex molecular genetic networks. These networks are larger and more interconnected than those of random disease pairs, suggesting shared underlying genetic mechanisms.

Area of Science:

  • Genomics
  • Molecular Biology
  • Computational Biology

Background:

  • Pre-eclampsia is a common pregnancy complication frequently co-occurring with diabetes mellitus, gestational diabetes, and obesity.
  • Understanding the molecular genetic basis of pre-eclampsia, especially its links to other pathologies, is crucial but currently limited.
  • Previous research indicated that inversely comorbid diseases share molecular genetic similarities.

Purpose of the Study:

  • To analyze the structural characteristics of genetic networks associated with comorbid diseases, focusing on pre-eclampsia.
  • To identify key molecular genetic mechanisms underlying pre-eclampsia development in the context of comorbidities.
  • To compare the genetic network properties of comorbid diseases with randomly selected disease pairs.

Main Methods:

  • Utilized ANDSystem, Pathway Studio, and STRING tools for text and database mining.
  • Reconstructed associative molecular genetic networks for comorbid disease pairs.
  • Employed computational approaches to analyze network size, connectivity, and gene interactions.

Main Results:

  • Associative networks for comorbid diseases (pre-eclampsia, diabetes mellitus, gestational diabetes, obesity) were statistically larger and more interconnected than random pairs.
  • Identified a 16-gene network connecting all four studied diseases.
  • Proposed potential molecular pathways involved in pre-eclampsia development, such as [TGFB1 or TNFA]-[IL1B]-[pre-eclampsia].

Conclusions:

  • Comorbid diseases, including pre-eclampsia, exhibit significantly larger and more connected molecular genetic networks compared to random disease pairs.
  • The structural organization of associative molecular genetic networks shows commonalities between comorbid and inversely comorbid diseases.
  • This study provides insights into the genetic underpinnings of pre-eclampsia and its relationship with metabolic disorders.
Abstract

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
37.3K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127